Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Combination therapy with α-CTLA-4 and α-PD-1 has shown significant clinical responses in different types of cancer. However, the underlying mechanisms remain elusive. Here, combining detailed analysis of human tumour samples with preclinical tumour models, we report that concomitant blockade of CTLA-4 and PD-1 improves anti-tumour immune responses and synergistically eradicates tumour. Mechanistically, combination therapy relies on the interdependence between IL-7 and IFN-γ signalling in T cells, as lack of either pathway abrogates the immune-boosting and therapeutic effects of combination therapy. Combination treatment increases IL-7Rα expression on tumour-infiltrating T cells in an IFN-γ/IFN-γR signalling-dependent manner, which may serve as a potential biomarker for clinical trials with immune checkpoint blockade. Our data suggest that combining immune checkpoint blockade with IL-7 signalling could be an effective modality to improve immunotherapeutic efficacy. Taken together, we conclude that combination therapy potently reverses immunosuppression and eradicates tumours via an intricate interplay between IFN-γ/IFN-γR and IL-7/IL-7R pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In line with these findings, microbes may reverse the resistance to immunotherapy through reactivation of IFN-ɤ signaling pathways.”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [94]
Experimental — accuracy not yet measuredIn the citing paper
“CTLA-4 blocking therapy of tumor-bearing mice also reportedly improves IFN-ɤ signaling in T cells (94).”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [94]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 1×
“We previously found that a -CTLA-4 blockade inhibits tumour growth and promotes tumour-free survival of tumour-bearing mice 4 , contributing to the recent FDA approval of ipilimumab, a human a -CTLA-4 monoclonal antibody that improves overall survival in patients with metastatic melanoma 5,6 .”
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×
“On a side note, identification of biomarkers that can predict which patients respond to cancer immunotherapy is an active research area 45 .”
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · cited 1×
“These findings, together with recent reports that blocking the PD-1/PD-L1 pathway improves overall survival and objective responses in patients with metastatic melanoma 7,8 , helped to establish a new field of ‘immune checkpoint blockade’.”
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231 · cited 1×
“IHC staining with PD-1 and PD-L1 staining has been described previously 55–57 .”
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878 · cited 1×
“A cardinal feature of immune checkpoint therapy is the induced durability of tumour rejection responses 2 .”
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · cited 1×
“We previously found that a -CTLA-4 blockade inhibits tumour growth and promotes tumour-free survival of tumour-bearing mice 4 , contributing to the recent FDA approval of ipilimumab, a human a -CTLA-4 monoclonal antibody that improves overall survival in patients with metastatic melanoma 5,6 .”
Cited by
The diverse functions of the PD1 inhibitory pathway
Sharpe, A. H., & Pauken, K. E. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.108 · Cited by 1,971
IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy
Ivashkiv, L. B. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0029-z · Cited by 1,358
Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy
Gao, J., Shi, L. Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S. E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.069 · Cited by 1,300
Self-citationRoles of IFN-γ in tumor progression and regression: A review
Jorgovanovic, D., Song, M., Wang, L., & Zhang, Y. (2020) · Biomarker Research · doi:10.1186/s40364-020-00228-x · Cited by 1,234
Bacterial outer membrane vesicles suppress tumor by interferon-γ-mediated antitumor response
Kim, O. Y., Park, H. T., Dinh, N. T. H., Choi, S. J., Lee, J., Kim, J. H., Lee, S.-W., & Gho, Y. S. (2017) · Nature Communications · doi:10.1038/s41467-017-00729-8 · Cited by 616
Gao, J., Ward, J. F., Pettaway, C. A., Shi, L. Z., Subudhi, S. K., Vence, L. M., Zhao, H., Chen, J., Chen, H., Efstathiou, E., et al. (2017) · Nature Medicine · doi:10.1038/nm.4308 · Cited by 594
Self-citationWang, C., Wang, J., Zhang, X., Yu, S., Wen, D., Hu, Q., Ye, Y., Bomba, H., Hu, X., Liu, Z., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan3682 · Cited by 591
Beyond immune checkpoint blockade: emerging immunological strategies
Kubli, S. P., Berger, T., Araujo, D. V., Siu, L. L., & Mak, T. W. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00155-y · Cited by 461
Bacterial outer membrane vesicles as a platform for biomedical applications: An update
Li, M., Zhou, H., Yang, C., Wu, Y., Zhou, X., Liu, H., & Wang, Y. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.04.031 · Cited by 370
Ménétrier-Caux, C., Ray-Coquard, I., Blay, J.-Y., & Caux, C. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0549-5 · Cited by 339
Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy
Beavis, P. A., Henderson, M. A., Giuffrida, L., Mills, J. K., Sek, K., Cross, R. S., Davenport, A. J., John, L. B., Mardiana, S., Slaney, C. Y., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89455 · Cited by 325
Naing, A., Infante, J. R., Papadopoulos, K. P., Chan, I. H., Shen, C., Ratti, N. P., Rojo, B., Autio, K. A., Wong, D. J., Patel, M. R., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.10.007 · Cited by 251
Advancing to the era of cancer immunotherapy
Wang, Y., Wang, M., Wu, H., & Xu, R. (2021) · Cancer Communications · doi:10.1002/cac2.12178 · Cited by 214
Sasson, S. C., Slevin, S. M., Cheung, V. T. F., Nassiri, I., Olsson-Brown, A., Fryer, E., Ferreira, R. C., Trzupek, D., Gupta, T., Al-Hillawi, L., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.06.025 · Cited by 210
Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8+ T Cell Apoptosis
Qiao, J., Liu, Z., Dong, C., Luan, Y., Zhang, A., Moore, C., Fu, K., Peng, J., Wang, Y., Ren, Z., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.05.005 · Cited by 176
Ding, H., Wang, G., Yu, Z., Sun, H., & Wang, L. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113683 · Cited by 159
Immune checkpoint blockade therapy
Wieder, T., Eigentler, T., Brenner, E., & Röcken, M. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.02.042 · Cited by 152
IL-2 and Beyond in Cancer Immunotherapy
Wrangle, J. M., Patterson, A., Johnson, C. B., Neitzke, D. J., Mehrotra, S., Denlinger, C. E., Paulos, C. M., Li, Z., Cole, D. J., & Rubinstein, M. P. (2018) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2017.0101 · Cited by 138
Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment
Saab, S., Zalzale, H., Rahal, Z., Khalifeh, Y., Sinjab, A. F., & Kadara, H. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00159 · Cited by 132
Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy
Shui, L., Yang, X., Li, J., Yi, C., Sun, Q., & Zhu, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02989 · Cited by 115
“CTLA-4 blocking therapy of tumor-bearing mice also reportedly improves IFN-È signaling in T cells (94).”
BackgroundZhong, Z., Vong, C. T., Chen, F., Tan, H., Zhang, C., Wang, N., Cui, L., Wang, Y., & Feng, Y. (2022) · Medicinal Research Reviews · doi:10.1002/med.21876 · Cited by 118
“Moreover, combined treatment with α‐CTLA‐4 and α‐PD‐1 blockade eradicates tumor synergistically by upregulating IL‐7Rα expression on tumor‐infiltrating T lymphocytes depending on IFN‐γ/IFN‐γ R pathways.(68) Notably, IFN‐γ stimulation increases the basal level or exosomal level of PD‐L1 to induce immunosuppression and…”
BackgroundShen, H., Ojo, O. A., Ding, H., Mullen, L. J., Xing, C., Hossain, M. I., Yassin, A., Shi, V. Y., Lewis, Z., Podgórska, E., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53593-8 · Cited by 101
Self-citationShi, J., Liu, J., Tu, X., Li, B., Tong, Z., Wang, T., Zheng, Y., Shi, H., Zeng, X., Chen, W., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003133 · Cited by 98
Cytokine-based Cancer Immunotherapy: Challenges and Opportunities for IL-10
Rallis, K. S., Corrigan, A. E., Dadah, H., George, A. M., Keshwara, S. M., Sideris, M. C., & Szabados, B. E. (2021) · Anticancer Research · doi:10.21873/anticanres.15110 · Cited by 92
NF-κB in Cancer Immunity: Friend or Foe?
Lalle, G., Twardowski, J., & Grinberg‐Bleyer, Y. (2021) · Cells · doi:10.3390/cells10020355 · Cited by 87
Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies
Shen, H., Yang, E. S.-H., Conry, M., Fiveash, J. B., Contreras, C. M., Bonner, J. A., & Shi, L. Z. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.06.006 · Cited by 84
Self-citationPrincipe, N., Kidman, J., Goh, S., Tilsed, C. M., Fisher, S. A., Fear, V. S., Forbes, C. A., Zemek, R. M., Chopra, A., Watson, M. W., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.584423 · Cited by 93
Xu, P., Yang, J. C., Chen, B., Nip, C., Dyke, J. E. V., Zhang, X., Chen, H., Evans, C. P., Murphy, W. J., & Liu, C. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006581 · Cited by 80
Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy
Zemek, R. M., Chin, W. L., Nowak, A. K., Millward, M., Lake, R., & Lesterhuis, W. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00223 · Cited by 75
“Combination anti-CTLA4 and anti-PD-1 work synergistically by increasing IFNγ signaling, which in turn increases IL-7 signaling, resulting in superior tumor eradication (78).”
BackgroundPirolli, N. H., Bentley, W. E., & Jay, S. M. (2021) · Advanced Biology · doi:10.1002/adbi.202000540 · Cited by 77
Liang, Y., Tan, Y., Guan, B., Guo, B., Xia, M., Li, J., Shi, Y. X., Yu, Z., Zhang, Q., Liu, D., et al. (2022) · Theranostics · doi:10.7150/thno.77281 · Cited by 69
Self-citationYang, Y., Jin, G., Pang, Y., Huang, Y., Wang, W., Zhang, H., Tuo, G., Wu, P., Wang, Z., & Zhu, Z. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00040 · Cited by 57
Lechner, M. G., Zhou, Z., Hoang, A. T., Huang, N., Ortega, J., Scott, L. N., Chen, H.-C., Patel, A. Y., Tafti, R. Y., Kim, K., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adg0675 · Cited by 63
Lechner, M. G., Patel, A. Y., Hugo, W., Angell, T. E., Cheng, M. I., Pioso, M. S., Hoang, A. T., Yakobian, N., McCarthy, E. C., Chen, H.-C., et al. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2200244 · Cited by 59
Emerging therapeutic role of gut microbial extracellular vesicles in neurological disorders
Sun, B., Sawant, H., Borthakur, A., & Bihl, J. C. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1241418 · Cited by 59
Surface Oncology, 5. H. S., Rausch, M. P., & Hastings, K. T. (2017) · Codon Publications eBooks · doi:10.15586/codon.cutaneousmelanoma.2017.ch9 · Cited by 75
Novel Combination Therapies for the Treatment of Bladder Cancer
Peng, M., Xiao, D., Bu, Y., Long, J., Yang, X. F., Lv, S., & Yang, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.539527 · Cited by 56
“The interactions among these immune cells are mediated by the interdependent loop between interleukin-7 (IL-7) and interferon gamma (IFN- g) signaling (27).”
BackgroundInfluentialRekers, N. H., Pimentel, V. O., Yaromina, A., Lieuwes, N. G., Biemans, R., Zegers, C. M. L., Germeraad, W. T. V., Limbergen, E. J. V., Neri, D., Dubois, L. J., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1414119 · Cited by 55
Attenuation of Innate Immunity by Andrographolide Derivatives Through NF-κB Signaling Pathway
Nie, X., Chen, S., Wang, K., Peng, Y., Wang, Y., Wang, D., Wang, Y., & Zhou, G. (2017) · Scientific Reports · doi:10.1038/s41598-017-04673-x · Cited by 50
Mouratidis, P., Costa, M. M., Rivens, I., Repasky, E. A., & ter Haar, G. (2021) · Journal of The Royal Society Interface · doi:10.1098/rsif.2021.0266 · Cited by 52
“Interface 18:(2)0210266 10 maximize immunotherapy potency over the use of each antibody alone as anecdotal observations showed that this ICI combination, when given every 3 days, resulted in improved therapeutic efficiency relative to treatment with either antibody alone [43,44].”
Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner
Shi, L. Z., Goswami, S., Fu, T., Guan, B., Chen, J., Xiong, L., Zhang, J., Tang, D. N., Zhang, X., Vence, L. M., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0873 · Cited by 49
Self-citationCD4+ T cells induce rejection of urothelial tumors after immune checkpoint blockade
Sato, Y., Bolzenius, J. K., Eteleeb, A. M., Su, X., Maher, C. A., Sehn, J. K., & Arora, V. K. (2018) · JCI Insight · doi:10.1172/jci.insight.121062 · Cited by 52
Rallis, K. S., Corrigan, A. E., Dadah, H., Stanislovas, J., Zamani, P., Makker, S., Szabados, B. E., & Sideris, M. C. (2022) · Future Oncology · doi:10.2217/fon-2022-0063 · Cited by 50
Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT
Duperret, E. K., Wise, M. C., Trautz, A., Villarreal, D. O., Ferraro, B., Walters, J. N., Yan, J., Khan, A. S., Masteller, E. L., Humeau, L. M. P. F., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.010 · Cited by 45
Jiang, X., Wu, H., Zhao, W., Ding, X., You, Q., Zhu, F., Qian, M., & Yu, P. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0789-y · Cited by 50
Single-Cell Analysis Reveals a CD4+ T-cell Cluster That Correlates with PD-1 Blockade Efficacy
Kagamu, H., Yamasaki, S., Kitano, S., Yamaguchi, O., Mouri, A., Shiono, A., Nishihara, F., Miura, Y., Hashimoto, K., Imai, H., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0112 · Cited by 47
Tseng, P., Chen, C., Lee, K.-Y., Feng, P., Wang, Y., Satria, R. D., & Lin, C. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215712 · Cited by 44
Recent Progress on Immunotherapy for Breast Cancer: Tumor Microenvironment, Nanotechnology and More
Yang, L., Miao, W., He, D., Wang, S., Lou, J., Jiang, Y., & Wang, S. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.680315 · Cited by 47
“Interferon γ (IFN-γ)is one of the essential effector molecules in antitumor immunity, and the loss of its receptor was found to completely abrogate the efficaciousness of ICB (Shi et al., 2016).”
BackgroundImmune-Based Therapy in Triple-Negative Breast Cancer: From Molecular Biology to Clinical Practice
Carlino, F., Diana, A., Piccolo, A., Ventriglia, A., Bruno, V., Santo, I. D., Letizia, O., Vita, F. D., Daniele, B., Ciardiello, F., et al. (2022) · Cancers · doi:10.3390/cancers14092102 · Cited by 44
“Furthermore, the production of interferon γ (IFN-γ) by activated TILs leads to PD-L1 and MHC-I upregulation, suggesting a crucial role for IFN-γ signaling in antitumor immune responses [46].”
BackgroundZibara, K., Zeidan, A., Bjeije, H., Kassem, N. A., Badran, B. M., & Zein, N. E. (2016) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-016-0362-6 · Cited by 45
Cytokines that target immune killer cells against tumors
Qiao, J., & Fu, Y. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0481-0 · Cited by 37
Local and Systemic IL-7 Concentration in Gastrointestinal-Tract Cancers
Bednarz‐Misa, I., Diakowska, D., & Krzystek‐Korpacka, M. (2019) · Medicina · doi:10.3390/medicina55060262 · Cited by 33
“This finding is in agreement with that made with regard to combination therapy with checkpoint inhibitors for bladder cancer [35], which demonstrated the interdependence of IL-7/IL-7R and IFN-γ/IFN-γR pathways, as well as their necessity for the”
ResultKos, Š., Lopes, A., Préat, V., Čemažar, M., Tratar, U. L., Učakar, B., Vanvarenberg, K., Serša, G., & Vandermeulen, G. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217762 · Cited by 34
Prummel, K. D., Woods, K., Kholmatov, M. M., Schmitt, E. C., Vlachou, E. P., Labyadh, M., Wehner, R., Poschmann, G., Stühler, K., Winter, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65803-y · Cited by 34
Hot or cold: Bioengineering immune contextures into in vitro patient-derived tumor models
Too, N. S. H., Ho, N. C. W., Adine, C., Iyer, N. G., & Fong, E. L. S. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.001 · Cited by 35
Chhabra, Y., Yong, X. L. H., Fane, M. E., Soogrim, A., Lim, W., Mahiuddin, D. N., Kim, R. S. Q., Ashcroft, M. M., Beatson, S. A., Ainger, S. A., et al. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12620 · Cited by 33
“Moreover, the efficacy of CTLA4/PD-1 combinatorial therapy is abrogated when IFN signalling is perturbed (Shi et al., 2016).”
BackgroundShen, H., Huang, F., Zhang, X., Ojo, O. A., Li, Y., Trummell, H. Q., Anderson, J. C., Fiveash, J. B., Bredel, M., Yang, E. S.-H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32754-7 · Cited by 30
Self-citationBridging Radiotherapy to Immunotherapy: The IFN–JAK–STAT Axis
Shi, L. Z., & Bonner, J. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212295 · Cited by 30
Self-citationZhao, J., Wu, Z., Yu, Y., Wang, L., & Li, C. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26548 · Cited by 29
“Recently, increasing evidence showed that IL-7 and IL7R play a role not only in the development of the immune system and maintenance of normal immune functions but also in the regulation of many autoimmune diseases (Monti & Bonifacio, 2014; Sahoo et al., 2016; Shi et al., 2016).”
BackgroundHe, X., Zhou, S., Dolan, M., Shi, Y., Wang, J., Quinn, B., Jahagirdar, D., Huang, W., Tsuji, M., Пили, Р., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003101 · Cited by 26
The many-sided contributions of NF-κB to T-cell biology in health and disease
Voisin, A., & Grinberg‐Bleyer, Y. (2020) · International review of cytology · doi:10.1016/bs.ircmb.2020.10.006 · Cited by 25
Informatics for cancer immunotherapy
Hammerbacher, J., & Snyder, A. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx682 · Cited by 24
Marshall, N., Hutchinson, K., Marron, T. U., Aleynick, M., Hammerich, L., Upadhyay, R., Svensson‐Arvelund, J., Brown, B. D., Mérad, M., & Brody, J. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0391 · Cited by 22
Effects of surgical trauma and intraoperative blood loss on tumour progression
Jin, X., Han, H., & Liang, Q. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1412367 · Cited by 20
Barroso‐Sousa, R., Zañudo, J. G. T., Li, T., Reddy, S. M., Emens, L. A., Kuntz, T. M., Silva, C. A. C., AlDubayan, S. H., Chu, H., Overmoyer, B. A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59695-1 · Cited by 18
Rolvering, C., Zimmer, A. D., Ginolhac, A., Margue, C., Kirchmeyer, M., Servais, F., Hermanns, H. M., Hergovits, S., Nazarov, P. V., Nicot, N., et al. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.ma1217-495r · Cited by 17
Sharma, A., Campbell, M. T., Yee, C., Goswami, S., & Sharma, P. (2019) · Elsevier eBooks · doi:10.1016/b978-0-7020-6896-6.00077-6 · Cited by 24
Self-citationTambaro, R., Napoli, M. D., Pisano, C., Cecere, S. C., Attademo, L., Rossetti, S., Feroce, F., Setola, S. V., Califano, D., Russo, D., et al. (2020) · Immunotherapy · doi:10.2217/imt-2020-0128 · Cited by 14
Atomic Force Microscopy in Mechanoimmunology Analysis: A New Perspective for Cancer Immunotherapy
Kristi, N., Gafur, A., Kong, L., Ma, X., Ye, Z., & Wang, G. (2020) · Biotechnology Journal · doi:10.1002/biot.201900559 · Cited by 17
Afshari, A. R., Sanati, M., Ahmadi, S. S., Kesharwani, P., & Sahebkar, A. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216955 · Cited by 15
Comprehensive analysis of inhibitory checkpoint ligand expression by glioblastoma cells
Robilliard, L. D., Yu, J. J., Anchan, A., Joseph, W. R., Finlay, G. J., Angel, C. E., & Graham, E. S. (2020) · Immunology and Cell Biology · doi:10.1111/imcb.12428 · Cited by 13
“upregulation of PD-1/PD-L1 interactions.(17) It is apparent that inhibitory checkpoint receptor signaling function in concert to mediate inappropriate immune downregulation.”
BackgroundA comprehensive review of mechanisms underlying resistance to immune checkpoint inhibitors
Bertucci, A., -, T. K., Billon, E., Fernez, T., & Rochigneux, P. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1735741 · Cited by 13
Wu, G., He, M., Ren, K., Ma, H., & Xue, Q. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s349441 · Cited by 13
Dramatic response of nivolumab-associated psoriasiform dermatitis to etoposide
Rios, A. A., Cen, P., Dinh, B., Mays, S. R., & Patel, A. B. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.11.025 · Cited by 12
Kanno, A. I., Goulart, C., Leite, L. C. C., Pagliarone, A. C., & Nascimento, I. P. (2019) · BioMed Research International · doi:10.1155/2019/9630793 · Cited by 12
Adaptive resistance in cancer immunotherapy
Yang, K. E., Yang, C., Xiong, K., Hao, J., & Ye, L. (2026) · Cellular and Molecular Immunology · doi:10.1038/s41423-026-01424-9 · Cited by 12
Immunotherapy for non-small cell lung cancer
Kagamu, H. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.01.011 · Cited by 13
Gfi1 controls the formation of effector-like CD8+ T cells during chronic infection and cancer
Ojo, O. A., Shen, H., Ingram, J. T., Bonner, J. A., Welner, R. S., Lacaud, G., Zajac, A. J., & Shi, L. Z. (2025) · Nature Communications · doi:10.1038/s41467-025-59784-1 · Cited by 10
Self-citationIso, H., Hisakane, K., Terashi, N., Mikami, E., Matsuki, S., Sonokawa, T., Atsumi, K., Yoshino, N., Nagata, K., Seike, M., et al. (2023) · Translational Cancer Research · doi:10.21037/tcr-23-221 · Cited by 10
“Also, combining anti-CTLA-4 and anti-PD-1 inhibitors treatment converts dysfunctional CD8 T-cells into activated effector CD8 T-cells and induces more infiltration of CD8 and CD4 T-cells into the tumor than does ICI monotherapy (17,18).”
The Role of Chemokine IL-7 in Tumor and Its Potential Antitumor Immunity
Zhang, L., Zhou, K., Biao, H., Huang, F., & Yigang, W. (2022) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2021.0236 · Cited by 9
Takeda, M., Kashima, S., Fuchigami, Y., Yoshino, T., Kataoka, T. R., Yamasaki, T., Kagamu, H., Kobayashi, T., & Akamatsu, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.934991 · Cited by 8
Hazra, R., Chattopadhyay, S., Mallick, A., Gayen, S., & Roy, S. (2024) · Medical Oncology · doi:10.1007/s12032-024-02416-3 · Cited by 8
“Studies on tumor-bearing mice undergoing CTLA-4 blocking therapy have also demonstrated improvements in IFN-gamma signaling in T cells [139].”
Antisense modulation of IL7R splicing to control sIL7R expression in human CD4 + T cells
Galarza-Muñoz, G., Kennedy-Boone, D., Schott, G., Bradrick, S. S., & García-Blanco, M. A. (2022) · RNA · doi:10.1261/rna.079137.122 · Cited by 8
“This is further supported by findings that the anti-tumor effects of αPD1 and α-CTLA4 combination therapy require a functional IL7/IL7R pathway (Shi et al. 2016).”
A drug-delivery depot for epigenetic modulation and enhanced cancer immunotherapy
Lai, J., Liang, J., Zhang, Y., Zhang, B., Wei, J., Fan, J., Chen, L., Chen, Z., Li, Q., Guo, D., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115687 · Cited by 7
Loss of PTDSS1 in tumor cells improves immunogenicity and response to anti–PD-1 therapy
Liu, J., Herbrich, S. M., Basu, S., Chen, Y., Nagarajan, A., Anandhan, S., Goswami, S., Xiong, L., Guan, B., & Sharma, P. (2025) · Science Advances · doi:10.1126/sciadv.adx8134 · Cited by 8
Self-citationHraboš, D., Hnízdilová, T., Tomala, J., Uhlík, J., & Kovář, M. (2020) · Cytokine · doi:10.1016/j.cyto.2020.155174 · Cited by 5
Recent advances in nanotechnology-based diagnosis and treatment of bladder cancer: an updated review
Hu, K., Cui, Y., Li, N., Li, P., Wang, X., & Chu, J. (2025) · International Journal of Smart and Nano Materials · doi:10.1080/19475411.2025.2493656 · Cited by 5
“For instance, combination therapy of anti-PD-1 and anti-CTLA-4 antibodies exhibited substantial preclinical and clinical results in bladder cancer [138].”
Revisiting the melanomagenic pathways and current therapeutic approaches
Dhanyamraju, P. K., Rotimi, S. O., Bhattacharya, P., & Patel, T. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07412-2 · Cited by 4
Chopra, A., Zamora, R., Yoram Vodovotz, B., Hodges, J. C., Barclay, D. A., Brand, R. E., Simmons, R. L., Lee, K. K. W., Paniccia, A., Murthy, P., et al. (2021) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000370 · Cited by 4
Predictive biomarkers of inhibitors immune checkpoints therapy in malignant tumors
Kiselevsky, M. V., Самойленко, И. В., Жаркова, О. В., Ziganshina, N. V., Petkevich, A., Ситдикова, С. М., Suleymanova, A. M., Sagoyan, G. B., Михайловна, Е. М., Киргизов, К. И., et al. (2021) · Russian Journal of Pediatric Hematology and Oncology · doi:10.21682/2311-1267-2021-8-2-73-83 · Cited by 4
Rios, A. A., Salazar, G. T., Zhang, N., & An, Z. (2019) · Antibody Therapeutics · doi:10.1093/abt/tbz003 · Cited by 3
“There has been limited use of combinations of checkpoint immune inhibitors due to exaggerated immune responses, leading to increased severity of side effects [19].”
BackgroundGao, L., & Chen, Y. (2023) · Biomedical Reports · doi:10.3892/br.2023.1619 · Cited by 3
Kamigaichi, A., Kagamu, H., Miyata, Y., Mimae, T., Tsubokawa, N., HIRANO, K., & Okada, M. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-026-04357-4 · Cited by 2
Cytokines in Cancer Immunotherapy
Sudan, R. (2020) · Springer eBooks · doi:10.1007/978-981-15-3350-1_10 · Cited by 3
Tanimura, K., Takeda, T., Kataoka, N., Yoshimura, A., Nakanishi, K., Yamanaka, Y., Yoshioka, H., Honda, R., Uryu, K., Fukui, M., et al. (2023) · Cancers · doi:10.3390/cancers15204988 · Cited by 2
“Under such conditions, an anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, which strongly activates the priming phase in combination with PD-1 antibodies, promotes the sensitization and activation of antigen-specific T cells [36].”
BackgroundHiJAKing Immunotherapy-Resistant Melanoma for a Cure
Shi, L. Z., Shen, H., Ojo, O. A., & Bonner, J. A. (2023) · The Oncologist · doi:10.1093/oncolo/oyac270 · Cited by 1
Self-citationEngineered MSCs enable bone marrow-targeted immunomodulation
Xu, S., Xu, J., Yang, Q., Zeng, J., Zhang, M., Wu, Y., Liu, Z., Wang, Q., You, Q., & Zhang, S. (2026) · Cell stem cell · doi:10.1016/j.stem.2026.03.003 · Cited by 1
Biomarkers predicting the effect of immunotherapy: what you need to know in practice?
Konstantinova, A. M. (2022) · Practical oncology · doi:10.31917/2302081 · Cited by 1
The Biomarkers of Cd4+ T Regulatory Cells Associated with Tumour Immune Escape
Nyaribari, M. (2020) · International Journal of Immunotherapy and Cancer Research · doi:10.17352/2455-8591.000028
“By contrast, excessive CD4+CD25hiCD127low/- mediated signaling can drive lymphoid leukemia development, disease acceleration and resistance to chemotherapy [49] combination therapy relies on the interdependence between IL-7 and IFN- signaling it increases CD4+CD25hiCD127low/- the expression on tumor-infi ltrating T c…”
BackgroundStudies of the role of sialyl Lewis X antigen and E selectin ligands in colorectal cancer
Deschepper, F. M. (2021) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Metadata
- Authors
- Shi, L. Z., Fu, T., Guan, B., Chen, J., Blando, J. M., Allison, J. P., Xiong, L., Subudhi, S. K., Gao, J., & Sharma, P.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Sharma, Padmanee
- ORCID
- Venue
- Nature Communications
- Published
- 2016-08-08
- Volume
- 7
- Issue
- 1
- Pages
- 12335-12335
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4979067
- OpenAlex
- W2519263052
- Cited by
- 111
- References
- 60
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 6 · 2023: 9 · 2022: 18 · 2021: 15 · 2020: 15 · 2019: 12 · 2018: 9 · 2017: 10 · 2016: 2
- FWCI
- 5.93
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Parker Institute for Cancer Immunotherapy
- National Institutes of Health (SU2C-CRI)
- University of Texas MD Anderson Cancer Center
- Stand Up To Cancer
- National Cancer Institute (R01 CA1633793, R01CA163793, CA1633793, P30CA016672)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CTLA-4 blockade, anti-PD-1 therapy, combination immunotherapy, tumor-infiltrating T cells, IFN-gamma receptor, immune checkpoint blockade, antitumor immunity, tumor immunosuppression, biomarkers
- MeSH terms
- Animals, Antineoplastic Combined Chemotherapy Protocols, Urinary Bladder Neoplasms, Female, Humans, Immunologic Memory, Interferon-gamma, Male, Mice, Inbred BALB C, Mice, Inbred C57BL, T-Lymphocytes, Signal Transduction, Interleukin-7, Up-Regulation, Lymphocytes, Tumor-Infiltrating, Receptors, Interleukin-7, Cell Line, Tumor, CTLA-4 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.